Free Trial
NASDAQ:IMA

ImageneBio Q3 2024 Earnings Report

ImageneBio logo
$14.67 -0.03 (-0.20%)
As of 08/8/2025 04:00 PM Eastern

ImageneBio EPS Results

Actual EPS
-$2.28
Consensus EPS
-$3.24
Beat/Miss
Beat by +$0.96
One Year Ago EPS
N/A

ImageneBio Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

ImageneBio Announcement Details

Quarter
Q3 2024
Time
N/A
Conference Call Date
Thursday, November 7, 2024
Conference Call Time
8:00AM ET

Upcoming Earnings

ImageneBio's next earnings date is estimated for Thursday, August 14, 2025, based on past reporting schedules.

Earnings Documents

ImageneBio Earnings Headlines

Musk’s Project Colossus could mint millionaires
I predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new millionaires than any tech advance in history. And for a limited time, you have the chance to claim a stake in this project, even though it’s housed inside Elon’s private company, xAI.
See More ImageneBio Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like ImageneBio? Sign up for Earnings360's daily newsletter to receive timely earnings updates on ImageneBio and other key companies, straight to your email.

About ImageneBio

ImageneBio (NASDAQ:IMA), a clinical-stage biotechnology company, develops therapeutics for immunological and inflammatory diseases. Its lead product includes IMG-007, a non-depleting anti-OX40 mAb that has completed Phase 2a clinical trials for the treatment of atopic dermatitis and alopecia areata. The company was formerly known as Ikena Oncology, Inc. and changed its name to ImageneBio, Inc. in July 2025. ImageneBio, Inc. is headquartered in San Diego, California.

View ImageneBio Profile

More Earnings Resources from MarketBeat